Mcl-1 Lentiviral Activation Particles (h): sc-400079-LAC

MCL1 encodes Mcl-1, an anti-apoptotic BCL-2 family protein that localizes primarily to the outer mitochondrial membrane and restrains mitochondrial outer membrane permeabilization by sequestering pro-death BH3-only factors and inhibiting BAX/BAK activation. Its abundance is tightly controlled by growth factor signaling and cellular stress through transcriptional programs and rapid proteasomal turnover, positioning Mcl-1 as a key node integrating survival cues with intrinsic apoptosis. MCL1 interfaces with pathways including PI3K/AKT, MAPK/ERK, and integrated stress responses that tune cell fate decisions under metabolic, genotoxic, or ER stress. Dysregulated MCL1 expression and dependency are frequently investigated in cancer and hematologic malignancy models, and altered apoptotic priming involving Mcl-1 is also relevant to studies of immune homeostasis and tissue injury biology.

Mcl-1 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient MCL1 upregulation across a broader range of human cell types.

Mcl-1 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the MCL1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous Mcl-1 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native MCL1 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.